


Moniliformin sodium salt

Cat. No.:	HY-101905
CAS No.:	71376-34-6
Molecular Formula:	C ₄ HNaO ₃
Molecular Weight:	120.04
Target:	Fungal; Antibiotic
Pathway:	Anti-infection
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	H ₂ O : 100 mg/mL (833.06 mM; Need ultrasonic)																			
	DMSO : ≥ 45 mg/mL (374.88 mM) * "≥" means soluble, but saturation unknown.																			
Preparing Stock Solutions	<table border="1"> <thead> <tr> <th rowspan="2">Solvent Concentration</th> <th colspan="3">Mass</th> </tr> <tr> <th>1 mg</th> <th>5 mg</th> <th>10 mg</th> </tr> </thead> <tbody> <tr> <td>1 mM</td> <td>8.3306 mL</td> <td>41.6528 mL</td> <td>83.3056 mL</td> </tr> <tr> <td>5 mM</td> <td>1.6661 mL</td> <td>8.3306 mL</td> <td>16.6611 mL</td> </tr> <tr> <td>10 mM</td> <td>0.8331 mL</td> <td>4.1653 mL</td> <td>8.3306 mL</td> </tr> </tbody> </table>	Solvent Concentration	Mass			1 mg	5 mg	10 mg	1 mM	8.3306 mL	41.6528 mL	83.3056 mL	5 mM	1.6661 mL	8.3306 mL	16.6611 mL	10 mM	0.8331 mL	4.1653 mL	8.3306 mL
	Solvent Concentration		Mass																	
		1 mg	5 mg	10 mg																
	1 mM	8.3306 mL	41.6528 mL	83.3056 mL																
5 mM	1.6661 mL	8.3306 mL	16.6611 mL																	
10 mM	0.8331 mL	4.1653 mL	8.3306 mL																	
Please refer to the solubility information to select the appropriate solvent.																				
In Vivo	1. Add each solvent one by one: PBS Solubility: 33.33 mg/mL (277.66 mM); Clear solution; Need ultrasonic																			

BIOLOGICAL ACTIVITY

Description	Moniliformin sodium salt is a potent mycotoxin isolate from <i>Fusarium moniliforme</i> .
In Vitro	<i>Fusarium moniliforme</i> NRRL 6322 produces about 600 mg of recoverable moniliformin, a mycotoxic metabolite, per kg of corn grit medium. Several strains of <i>Fusarium moniliforme</i> produce in laboratory culture more than 800 mg of moniliformin per kg of growth substrate ^[1] . Monocytes-derived macrophages exposed to moniliformin during the differentiation process present a decrease of endocytosis ability, and a decrease of CD71 and HLA-DR expression ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Moniliformin is less toxic to mice, with an LD ₅₀ of 20.9 mg per kg for the females and 29.1 mg per kg of body weight for the males. As in the case of the chicks, mice surviving the toxin demonstrated no ill effects; the mice or chicks that died became recumbent in 4 to 6 h after treatment and died within 24 h. In 4-day-old chicken embryos, a sharp LD ₅₀ of 2.8 µg per embryo is obtained with no overt gross teratogenic effects in the survivors ^[1] . Rats treated with the highest dose of moniliformin

show decreased activity followed by acute heart failure and death. The rats of the lower doses (<9mg/kg b.w.) show no signs of toxicity. The daily intake of moniliformin strongly reduces the phagocytic activity of neutrophils in all dose groups. The decrease continued in the satellite group during the follow-up period, indicating a severe impact on the immune system and a LOAEL value of 3mg/kg b.w. for moniliformin. Moniliformin is rapidly excreted into urine, ranging between 20.2 and 31.5% daily and shows no signs of accumulation. The concentration of moniliformin in faeces is less than 2%, which suggests efficient absorption from the gastrointestinal tract^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Animal Administration ^{[1][3]}

Rats: Moniliformin is prepared in water. In this experiment, 5 dose groups (3, 6, 9, 12 and 15 mg/kg moniliformin b.w.) of test animals are exposed to moniliformin for 28 days. Each group consists of 5 male Sprague-Dawley rats. The dose groups are determined based on our acute toxicity study of MON in rats. In addition, a control group administered with filtered tap water and two satellite groups (dosed 12 and 15 mg/kg b.w. moniliformin) are used. The two satellite groups are kept alive for an additional 14 days without treatment to detect possible delayed toxic effects and to follow up recovery^[3].

Mice: Sterile aqueous solutions of moniliformin are injected intraperitoneally (0.2 mL) into five female and five male white mice, weighing about 25 g each, at concentrations equivalent to 0, 20, 25, 30, and 35 mg per kg of body weight. The mice are observed over a 4-day period, and LD₅₀ values are determined^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Burmeister HR, et al. Moniliformin, a metabolite of *Fusarium moniliforme* NRRL 6322: purification and toxicity. *Appl Environ Microbiol.* 1979 Jan;37(1):11-3.
- [2]. Ficheux AS, et al. Effects of beauvericin, enniatin b and moniliformin on human dendritic cells and macrophages: an in vitro study. *Toxicol.* 2013 Sep;71:1-10.
- [3]. Jonsson M, et al. Repeated dose 28-day oral toxicity study of moniliformin in rats. *Toxicol Lett.* 2015 Feb 17;233(1):38-44.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA